Dare Bioscience Inc. Common Stock (DARE)

About DARE

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topic…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

21

Website

www.darebioscience.com/

Fundamentals

1-day range

$0.72$0.758

Market cap

$19.17M

P/E (trailing)

—

P/E (forward)

-1.77

EPS (trailing)

$-0.59

Dividend yield

—

Beta

1.03

Avg. volume

486.4K

Dividend pay date

July 20, 2017

Forecasts

3 analyst ratings

Dare Bioscience Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.17MP/E —
  $0.72$3.78
• ALLR

  Allarity Therapeutics Inc. Common Stock

  $1.41

  ▲ 2.17%
  Market cap $19.64MP/E —
  $0.769$2.06
• PLRZ

  Polyrizon Ltd. Ordinary Shares

  $12.7

  ▼ 0.78%
  Market cap $19.82MP/E —
  $2.88$18.2
• NCEL

  NewcelX Ltd. Ordinary Shares

  $3.19

  ▼ 6.73%
  Market cap $18.41MP/E —
  $1.83$24.6
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $20.34MP/E —
  $0.8099$2.46
• SKYE

  Skye Bioscience Inc. Common Stock

  $1.81

  ▼ 7.18%
  Market cap $20.53MP/E —
  $1.84$39.92
• RKTO

  Rocket One Inc. Common Stock

  $0.7021

  ▼ 2.76%
  Market cap $17.64MP/E —
  $0.691501$2.45

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
  benzinga · 8/26/2026
• Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
  SeekingAlpha · 8/26/2026
• Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
  Benzinga · 8/26/2026
• Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
  Benzinga · 8/26/2026
• 12 Health Care Stocks Moving In Friday's Intraday Session
  Benzinga · 8/14/2026
• Daré Bioscience Announces $6M Offering Of 4,379,581 Shares (Or Pre-Funded Warrants To Purchase Shares Of Common Stock In Lieu Thereof) At $1.37/Share
  Benzinga · 8/14/2026
• Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Stay updated with the stocks that are on the move in today's after-hours session.
  ChartMill · 8/13/2026
• Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript
  Benzinga · 8/13/2026

• Gregory W. Matz · June 30, 2026 · Grant

  30.8K
• Robin Joan Steele · June 30, 2026 · Grant

  26.5K
• William H. Rastetter · June 30, 2026 · Grant

  38.9K
• Jessica D. Grossman · June 30, 2026 · Grant

  26.1K
• Susan L. Kelley · June 30, 2026 · Grant

  23.7K
• Jessica D. Grossman · June 11, 2026 · Grant

  10.0K
• Gregory W. Matz · June 11, 2026 · Grant

  10.0K
• Susan L. Kelley · June 11, 2026 · Grant

  10.0K
• Robin Joan Steele · June 11, 2026 · Grant

  10.0K
• William H. Rastetter · June 11, 2026 · Grant

  10.0K

Institutional Ownership

March 31, 2026

Total shares held

955.9K

Total value held

$1.72M

Institutional holders

23